Funding Round attributes
Quanta Dialysis Technologies, a medical technology company based in Warwick, UK, has successfully closed a Series E funding round, raising over $60 million. The round was led by Novo Holdings, Glenview Capital, and b2venture, with participation from existing investors.
Founded with the mission to transform kidney care, Quanta has developed the Quanta™ Dialysis System, designed to make dialysis accessible to patients across various settings. The system offers clinical versatility, enabling the delivery of kidney replacement therapy in multiple care environments. Its user-friendly design allows operation by a broad range of users, facilitating direct patient access to dialysis treatments.
In 2022, Quanta received clearance for the first and only FDA-cleared device capable of performing intermittent hemodialysis (IHD), sustained low-efficiency dialysis (SLED), and continuous renal replacement therapy (CRRT) modalities, including continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF), without the need for bags. In 2024, the company achieved FDA clearance for home hemodialysis (HHD), offering a high dialysate flow system of 500 mL/min.
The newly secured funds are intended to expand Quanta's commercial presence in the United States and to continue investing in innovation within the dialysis sector. This strategic focus aims to enhance the accessibility and quality of dialysis care for patients, aligning with the company's commitment to improving kidney care globally.
The Series E funding round reflects strong investor confidence in Quanta's technology and its potential to address critical needs in kidney care. The participation of leading investment firms underscores the significance of Quanta's advancements in dialysis treatment and their impact on patient care.
Quanta's CEO, Alejandro Galindo, leads the company in its efforts to revolutionize dialysis treatment. Under his leadership, Quanta continues to focus on developing solutions that provide flexibility and accessibility in dialysis care, aiming to improve patient outcomes and quality of life.
The successful completion of the Series E funding round marks a significant milestone for Quanta Dialysis Technologies. With the additional capital, the company is well-positioned to advance its mission of transforming kidney care through innovative dialysis solutions, benefiting patients and healthcare providers alike.
